Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.
This search will output a list of trials for which you may be eligible based on the criteria you enter.
For more detailed information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.
|NCT05257408||III||Platinum resistant high grade serous or high grade endometrioid ovarian cancer that must have had prior bevacizumab||A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel Versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA)||AZ, CA, CO, FL, GA, IL, IN, KS, KY, NJ, NM, NY, OH, OR, PA, SD, TN, TX, VA, WI||View Drugs||View Results |
|nab-Paclitaxel||Paclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007||Microtubule stabilizer/mitotic inhibitor||NCCN Guidelines for Ovarian Cancer|
|Relacorilant||RELA, CORT125134||GR antagonist||Clinical Trials|